THOR MEDICAL |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.08 NOK | 0.00% |
|
+1.31% | -16.28% |
| 02-28 | Transcript : Thor Medical ASA, H2 2023 Earnings Call, Feb 28, 2024 | |
| 02-14 | Thor Medical ASA Announces CEO Changes | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 301M 3.32B 24.07B |
|---|---|---|---|---|---|
| Net income 2022 | -311M -3.43B -24.85B | Net income 2023 | -26M -286M -2.08B | EV / Sales 2022 * | - |
| Net cash position 2022 | 98.56M 1.09B 7.88B | Net cash position 2023 | 41.77M 460M 3.34B | EV / Sales 2023 | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-8.49
x | Employees | 2 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 36.07% |
More Fundamentals
* Assessed data
More news
Latest transcript on Thor Medical
More news
| 1 week | +1.31% | ||
| Current month | +0.56% | ||
| 1 month | +0.56% | ||
| 3 months | -9.70% | ||
| 6 months | -13.32% | ||
| Current year | -16.28% |
1 week
1.03
1.12
1 month
0.961.53
Current year
0.851.53
1 year
0.852.30
3 years
0.852.30
5 years
0.852.30
10 years
0.852.30
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1.08 | +1.89% | 153,183 |
| 25/04/24 | 1.06 | 0.00% | 88,337 |
| 24/04/24 | 1.06 | +1.15% | 114,070 |
| 23/04/24 | 1.048 | -2.96% | 186,792 |
| 22/04/24 | 1.08 | +1.31% | 635,291 |
Real-time Oslo Bors, April 26, 2024 at 03:45 pm
More quotes
Thor Medical ASA, formerly Nordic Nanovector ASA, is a Norway-based biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product is Betalutin, a CD37-targeting radio-immunoconjugate designed to advance the treatment of non-Hodgkin lymphoma (NHL). Betalutin uses monoclonal antibodies to attack the cancer cells in two ways, first as an immunotherapy and secondly as a targeting agent for a radioactive payload and is a combination of radiation therapy and immunotherapy. The Company is also leveraging its expertise in radionuclides and CD37-targeting antibodies, along with partners, to build a pipeline of biopharmaceuticals for a range of haematological cancers.
Calendar
29/08/2024
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -16.28% | 22.97M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- TRMED Stock
